Protective effects of pamiteplase, a modified t-PA, in a rat model of embolic stroke.

Abstract

The effects of alteplase (tissue plasminogen activator, t-PA) and pamiteplase (a modified t-PA with longer half-life and increased potency) were compared in a clinically relevant model of embolic stroke. Rats were treated with pamiteplase (0.5 mg/kg or 1 mg/kg bolus), alteplase (10 mg/kg infusion) or normal saline. Pamiteplase (1 mg/kg) was as effective as alteplase in reducing 24 h brain infarct volumes, neurological deficit scores and residual clot grades. Cerebral blood flow recovery at 30 min after thrombolytic treatment was partial and did not correlate with 24 h infarct volumes or neurological deficits. However, there was good correlation between 24 h residual clot grades and infarct volumes, suggesting a delayed timeframe for pamiteplase- and alteplase-induced reperfusion.

• Authors: T Sumii, A B Singhal, M Asahi, M Shimizu-Sasamata, M Suzuki, K Miyata, E H Lo
• Journal: Neuroreport (Neuroreport) Vol. 12 Issue 3 Pg. 615-8 (Mar 05 2001) ISSN: 0959-4965 [Print] England
• PMID: 11234775 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Neuroprotective Agents
• Recombinant Proteins
• Tissue Plasminogen Activator
• pamiteplase

Topics

• Animals
• Cerebrovascular Circulation (drug effects)
• Disease Models, Animal
• Intracranial Embolism (drug therapy)
• Laser-Doppler Flowmetry
• Male
• Neuroprotective Agents (pharmacology)
• Rats
• Rats, Sprague-Dawley
• Recombinant Proteins (pharmacology)
• Stroke (drug therapy)
• Thrombolytic Therapy
• Tissue Plasminogen Activator (pharmacology)